On March 30, 2012 Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") reported that it has entered into a worldwide licensing agreement with OncoTherapy Science, Inc. (Head Office: Kawasaki, Kanagawa; President & CEO: Takuya Tsunoda, Ph.D.; hereafter "OTS") to develop, manufacture and market cancer peptide vaccines (Press release, Shionogi, MAR 30, 2012, View Source [SID1234556291]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Shionogi had previously announced a licensing agreement with OTS on February 2, 2009 for specific peptides related to five different types of oncoantigens*, discovered by OTS, which are highly expressed on cancer cells. Since that agreement became effective, Shionogi has been globally developing therapeutic vaccines incorporating these oncoantigen peptides for the treatment of patients with several types of cancers, including bladder cancer and esophageal cancer. With the completion of this new agreement, Shionogi is expanding its relationship with OTS to encompass worldwide rights to peptide vaccines discovered by OTS, for all indications. As part of this new agreement, OTS will receive an up-front payment, milestone payments at successful completion of key phases, and royalties on sales.
This expanded alliance demonstrates Shionogi’s dedication to developing innovative treatment options, as quickly as possible, for the benefit of patients worldwide.
* Oncoantigens are protein antigens that are specifically expressed in tumor cells but not in healthy cells, are critical for cancer cell growth, and are highly antigenic, effectively inducing Cytotoxic T Lymphocytes (CTL) to help target and destroy tumor cells expressing the oncoantigen without killing healthy cells.